



PRESS RELEASE

Transgene Announces Financial Calendar for 2026

Strasbourg, France, February 4, 2026, 5:45 p.m. CET – **Transgene (Euronext Paris: TNG)** a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, **today announces its financial reporting and Annual shareholders' meeting dates for 2026:**

March 24, 2026: 2025 Fiscal Year Results

April 29, 2026: First Quarter 2026 Financial Results

May 13, 2026: Annual Shareholders' Meeting

September 24, 2026: First Half 2026 Financial Results

November 9, 2026: Third Quarter 2026 Financial Results

Contacts

Transgene

Media:

Caroline Tosch

Corporate and Scientific Communications Manager

+33 (0)3 68 33 27 38

communication@transgene.fr

MEDISTRAVA

Frazer Hall/Sylvie Berrebi

+ 44 (0)203 928 6900

transgene@medistrava.com

Investors & Analysts:

Lucie Larguier

Chief Financial Officer (CFO)

Nadege Bartoli

Investor Relations Analyst

and Financial Communications Officer

+33 (0)3 88 27 91 00/03

investorrelations@transgene.fr

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the *myvac*® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The Company has other viral vector-based assets, including BT-001, an oncolytic virus based on the Invir.IO® viral backbone, which is in clinical development. The Company also conducts innovative discovery and preclinical work, aimed at developing novel immunotherapies.

With Transgene's *myvac*® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The *myvac*® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

Additional information about Transgene is available at: www.transgene.com

Follow us on social media: X (formerly Twitter): [@TransgeneSA](https://twitter.com/TransgeneSA) — LinkedIn: [@Transgene](https://www.linkedin.com/company/transgene/) — Bluesky: [@Transgene](https://bluesky.social/@Transgene)

Disclaimer

This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (<http://www.amf-france.org>) or on Transgene's website (www.transgene.com). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.